New blood test finds early risk for ovarian cancer

Researchers have identified a molecular signal in the blood, specifically an RNA molecule called Tu-Stroma, that can detect early-stage ovarian cancer. This breakthrough could allow for earlier intervention before invasive cancer develops, potentially transforming preventative care for high-risk women.
Why it matters
Early detection of ovarian cancer is notoriously difficult, and this diagnostic tool could significantly improve survival rates and reduce the need for unnecessary preventative surgeries.
A molecular signal in the blood helps identify microscopic changes that precede the development of ovarian cancer, researchers have found, in a potential diagnostic breakthrough for a disease often discovered after it has already spread. For decades, efforts to detect ovarian cancer earlier have focused on finding smaller tumours, the researchers noted in their report published on Tuesday in Nature Medicine. “We asked a fundamentally different question: What if we could identify the earliest molecular warning signs before invasive cancer even develops?” study leader Rajan Gogna of the Hoag Family Cancer Institute in Newport Beach, California, said in a statement. Ovarian cancer often begins with microscopic changes in the lining of the fallopian tubes. The precancerous lesions are known as serous tubal intraepithelial carcinoma (STIC).
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in